Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes tardive dyskinesia: No clinically important improvement compared with OTHER DRUGS (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes tardive dyskinesia: Deterioration compared with OTHER DRUGS (very low certainty).
1 finding from 1 review
Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Mental state ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with OTHER DRUGS (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
DOPAMINERGIC DRUGS may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes tardive dyskinesia: Deterioration compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
General mental state: Deterioration · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes general mental state: Deterioration compared with PLACEBO (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Mental state ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes tardive dyskinesia: No clinically important improvement compared with DOPAMINERGIC DRUGS (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review